Ivax Launch Of Generic Neurontin Raises Eyebrows

Law360, New York (August 19, 2004, 12:00 AM EDT) -- Ivax Corp.’s decision Wednesday to launch a generic version of Pfizer Inc.'s blockbuster epilepsy drug Neurontin in the midst of a drawn-out patent dispute is seen by analysts as a bold but risky move.

Ivax said Wednesday that it was carrying out only a "limited" launch to a small number of buyers, most likely pharmacy-benefit managers and managed-care organizations.

Under most state pharmacy laws, Ivax's generic tablet may not technically be substitutable for Pfizer's Neurontin in the same strengths, given that it is a tablet formulation...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.